Innoplexus AG is a leading global AI-powered software company, offering SaaS-based platform “Ontosight®” for drug discovery and development. With over 300 employees and 125+ patent applications, including 60+ grants, our IP in artificial intelligence, machine learning and blockchain technologies, is one of a kind.
We live in an era of global transformation, where scientific knowledge, human data and AI/ML shape the future of drug discovery as well as a multitude of other aspects of our lives in the 21st century. Our proprietary solutions generate real-time insights from hundreds of terabytes of structured and unstructured proprietary and public data. Thereby, we facilitate continuous, informed decision-making for our customers at an unparalleled speed. We support all stages of drug discovery and development from pipeline to market to commercialization.
Our core strengths in virtual drug discovery include prioritization of drug targets and indications, prediction of undesirable adverse effects and clinical trial outcomes of therapeutic interventions in a therapeutic area- and modality-independent fashion, to name just a view.
Founded in 2015, Innoplexus AG is headquartered in Eschborn, Germany, with offices in Pune, India, and Iselin/NJ, United States.
For more info, please visit www.innoplexus.com